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 2012 EMBO Molecular MedicineThe genetic or functional inactivation of p53 is highly prevalent in human
cancers. Using high-content videomicroscopy based on fluorescent TP53þ/þ
and TP53/ human colon carcinoma cells, we discovered that SP600125, a
broad-spectrum serine/threonine kinase inhibitor, kills p53-deficient cells more
efficiently than their p53-proficient counterparts, in vitro. Similar observations
were obtained in vivo, in mice carrying p53-deficient and -proficient human
xenografts. Such a preferential cytotoxicity could be attributed to the failure of
p53-deficient cells to undergo cell cycle arrest in response to SP600125. TP53/
(but not TP53þ/þ) cells treated with SP600125 became polyploid upon mitotic
abortion and progressively succumbed to mitochondrial apoptosis. The expres-
sion of an SP600125-resistant variant of themitotic kinase MPS1 in TP53/ cells
reduced SP600125-induced polyploidization. Thus, by targeting MPS1,
SP600125 triggers a polyploidization program that cannot be sustained by
TP53/ cells, resulting in the activation of mitotic catastrophe, an oncosup-
pressive mechanism for the eradication of mitosis-incompetent cells.INTRODUCTION
The genetic or functional inactivation of the tumour suppressor
p53 is (one of) the most frequent molecular characteristic(s) of
human cancer (Cheok et al, 2011). It has been estimated that
nowadays 11 million people are living with a cancer thatance
e, Italy
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þ33 1 4211 6047;contains an inactivating mutation of TP53 and additional
11 millions have neoplasms in which the p53 pathway is
interrupted due to defects in the molecules that act either
upstream or downstream of p53 (Brown et al, 2009).
p53 has recently been shown to control cellular homeostasis
via multiple mechanisms (Vousden & Ryan, 2009). Still, p53 is
best known as the major mediator of the cellular response to
stress, a phenomenon that entails both transcriptional (nuclear)
and non-transcriptional (cytoplasmic) p53 functions (Green &
Kroemer, 2009; Vousden & Prives, 2009). Thus, in response to
adverse conditions, p53 can stimulate the execution of apoptotic
cell death, mainly through the transactivation of several pro-
apoptotic genes (Beckerman & Prives, 2010) or physical
interactions with proteins that regulate mitochondrial outer
membrane permeabilization (Galluzzi et al, 2011a). Alterna-
tively, stress-activated p53 can arrest the cell cycle, either by
transactivating inhibitors of cyclin-dependent kinases or,
perhaps, by direct interactions with essential cell cycle
regulators (Tritarelli et al, 2004). Therefore, p53-deficient cells
are notoriously resistant against the induction of apoptosis
(Cheok et al, 2011) and fail to undergo cell cycle arrest inEMBO Mol Med 4, 500–514 www.embomolmed.org
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genomically instable (Talos & Moll, 2010). The absence of p53
reportedly favours spontaneous tetraploidization in several
distinct contexts (Davoli & de Lange, 2011; Ganem et al, 2007).
Moreover, in response tomitotic inhibitors such asmicrotubular
poisons, p53-incompetent cells can overridemitotic checkpoints
and hence can become polyploid, a property that is thought to
contribute to chromosomal instability (Aylon et al, 2006; Finkin
et al, 2008; Ha et al, 2007; Vitale et al, 2010) as well as to
resistance to chemo- and radiotherapy (Castedo et al, 2006;
Galluzzi et al, 2011b; Shen et al, 2008).
Thus, p53 plays a prominent role in coupling the effects of
DNA damaging agents (such as ionizing radiations or chemicals
including platinum derivatives and topoisomerase inhibitors) to
the therapeutic induction of senescence or apoptosis. Given the
prevalence and functional impact of p53 defects, many groups
have attempted to identify pharmacological agents that
preferentially kill p53-incompetent cells (Brown et al, 2009).
While some of these compounds directly interact with mutant
p53 proteins and reestablish their functions via conformational
effects (Athar et al, 2011; Selivanova, 2010; Wiman, 2010),
others were designed to inhibit the p53-targeting ubiquitin ligase
HDM2, leading to increased p53 concentrations (Shangary &
Wang, 2009). Moreover, some agents kill p53-deficient cancer
cells based on their increased tendency to undergo polyploidi-
zation. VX-680 (an inhibitor of Aurora kinases) causes the
endoreplication of p53-deficient cells, resulting in their death
(Gizatullin et al, 2006). A combination of irradiation and BI-
2536 (a inhibitor of Polo-like kinase 1, PLK1) kills TP53/ cells
more efficiently than their TP53þ/þ counterparts (Sur et al,
2009), and the selective toxicity of GSK461364A (another PLK1
inhibitor) against p53-deficient cells has been attributed to their
failure to undergo cell cycle arrest at a tetraploid stage
(Degenhardt et al, 2010). Similarly, 7-hydroxystaurosporine
(UCN-01, an inhibitor of the checkpoint kinase CHEK1) has been
shown to abrogate DNA damage-induced cell cycle arrest
selectively in p53-defective cancer cells (Levesque et al, 2005).
In this study, we launched yet another attempt to identify
compounds that kill p53-deficient cells more efficiently than
their p53-positive counterparts. Using a novel videomicroscopic
assay, we identified SP600125 as an agent whose cytotoxicity is
exacerbated in conditions in which p53 is deleted, depleted or
inhibited, in vitro and in vivo. The mechanisms through which
SP600125 mediates these effects involve the selective poly-
ploidization of p53-deficient cells due to the inhibition of the
mitotic kinase MPS1. Preferentially in the context of p53
deficiency, this results in abortive mitosis, followed by the
activation of mitotic catastrophe and cell death via the
mitochondrial pathway of apoptosis.RESULTS AND DISCUSSION
Identification of SP600125 as a selective inhibitor
of p53-deficient cells
p53-deficient (TP53/) human colon carcinoma HCT 116 cells
or their p53-proficient wild-type (WT) counterparts stablywww.embomolmed.org EMBO Mol Med 4, 500–514expressing red fluorescent protein (RFP)- or green fluorescent
protein (GFP)-tagged histone 2B, respectively, were co-cultured
in 96-well plates for 48 h in the absence or presence of 480
distinct compounds from the ICCB library of bioactive agents.
Throughout this period, the ratio of greenWT versus red TP53/
HCT 116 cells was quantitatively monitored by videomicro-
scopy. In line with the fact that p53 often mediates the cytotoxic
effects of DNA-damaging agents, 10-hydroxycamptothecin and
cisplatin depleted more efficiently WT than TP53/ cells. In
contrast SP600125, a broad-spectrum inhibitor of serine/
threonine kinases including Aurora kinase A (IC50¼ 60 nM)
and B (190 nM), CDC7/DBF4 (1.59mM), CDK2/CYCA (880 nM),
CK2 (650 nM), FLT3 (90 nM), Haspin (510 nM), IKK2 (1mM),
JAK3 (410 nM), KIT (870 nM), MELK (110 nM), PDK1
(1.06mM), PIM2 (1.05mM), RET (1.09mM), SYK (1.8mM),
TRKA (70 nM), TYK2 (880 nM) and VEGFR3 (300 nM) (Colombo
et al, 2010), but best known for inhibiting c-Jun N-terminal
kinases (JNK) 1–3 (100–200 nM) (Bennett et al, 2001; Heo et al,
2004) and MPS1 (IC50 1.95mM) (Chu et al, 2008; Schmidt et al,
2005), was the most efficient agent in increasing the ratio
between WT and TP53/ cells (Fig 1A–C). These results are
consistent with previous observations (Mingo-Sion et al, 2004),
andwere validated using two alternativemethods formeasuring
cell proliferation and death, namely the xCELLigence1 system,
which quantifies the impedance of adherent cells (Fig 1D), and
cytofluorometry (Fig 1E) (Castedo et al, 2002; Galluzzi et al,
2009, 2007). Upon co-staining with the vital dye propidium
iodide (PI) and the mitochondrial transmembrane potential
(Dcm) sensor DiOC6(3), the frequency of dying (DiOC6(3)
low
PI) and dead (DiOC6(3)
low PIþ) cells was markedly increased
among SP600125-treated TP53/ cells but less so among WT
control cells (Fig 1E). Altogether, these results suggest that
SP600125 is endowed with the capacity of selectively killing
p53-deficient tumour cells.
Polyploidization of p53-deficient cells responding
to SP600125
Since SP600125 can perturb mitosis and/or induce endoreplica-
tion (Kim et al, 2010; Schmidt et al, 2005) we investigated its
effect on the cell cycle of WT and TP53/ HCT 116 cells. WT
cells treated with SP600125 progressively acquired a 4n DNA
content (which corresponds to the normal amount of DNA
in the G2 or M phase of the cell cycle), while TP53
/ cells
accumulated a higher DNA content (8n or 16n), indicating that
they became tetraploid or higher-order polyploid (Fig 2A and B).
Accordingly, SP600125 blocked the incorporation of the
thymidine analog 5-ethynyl-20-deoxyuridine (EdU) into DNA
inWT but not in TP53/ cells. Moreover, at odds with their WT
counterparts, TP53/ cells continued to incorporate EdU even
when they possessed a 4n or 8n DNA content (Fig 2C). A
significant fraction of TP53/ (but not WT) cells exhibited
histone H3 phosphorylation, an indicator of ongoing mitosis, or
stained positively for themitotic-specific phosphoepitopeMPM2
at the 8n stage (Fig 2D and Fig S1 of Supporting Information),
Moreover, in response to SP600125, WT (but not TP53/) cells
exhibited a marked decline in cyclin B (the cyclin associated
with the G2/M phase) levels and increased amounts of cyclin E 2012 EMBO Molecular Medicine 501
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Figure 1. Identification of SP600125 as a selective inhibitor of p53-deficient cells.
A-C. Screening of the ICCB Known Bioactives Library onWT (GFP-H2B-expressing) and TP53/ (RFP-H2B-expressing) human colon carcinoma HCT 116 cells. Cells
were co-cultured at an initial 1:1 ratio in the absence (Co) or presence of 480 distinct signal transduction inhibitors and the capacity of the agents to change
the ratio between GFP and RFP-labelled cells was assessed over 48 h by epifluorescence videomicroscopy. The Z-score analysis for all 480 components is
reported in (A), snapshots taken at 48 h are shown in (B) (scale bar¼10mm) and representative changes in theWT/TP53/ cell ratio upon 30mMSP600125
or 20mM cisplatin (CDDP) administration are depicted in (C).
D,E. Confirmation of the preferential effect of SP600125 on TP53/ cells. HCT 116 cells with the indicated genotype were cultured on plates that allow for the
real-time measurement of impedance of adherent cells (for more details refer to Materials and Methods Section), in the presence or absence of 30mM
SP600125, and the slope of the growth curve was determined for triplicates SEM (D). Alternatively, cells left were left untreated or incubated with the
indicated concentration of SP600125 or CDDP for the indicated time, followed by cytofluorometry for the assessment of cell death-related parameters.
Green/red and black columns illustrate the percentage of dying (PI DiOC6(3)
low) and dead (PIþ) cells, respectively (means SEM; n¼ 9). p< 0.05 (Student’s
t-test).
502  2012 EMBO Molecular Medicine EMBO Mol Med 4, 500–514 www.embomolmed.org
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Figure 2. Selective polyploidization of p53-
deficient cells in response to SP600125.
A,B. Cell cycle analysis. WT and TP53/ human
colon carcinoma HCT 116 cells were exposed to
the indicated dose of SP600125 (30mM where
not specified) for the indicated time, followed
by the assessment of cell cycle distribution.
Panel (A) reports representative cell cycle
distributions, panel (B) depicts quantitative
data (means SEM; n¼9).
C-F. Paradoxical antiproliferative effects of
SP600125. p53-proficient and p53-deficient
cells were cultured in the presence of 30mM
SP600125 as indicated and either labelled with
the thymidine analogue EdU during the last
30min of the assay, followed by fixation and
detection of EdU fluorescence (C) or subjected
to the immunodetection of phospho-histone
H3 (pH3) (D). PI was used to label DNA prior to
cytofluorometric acquisitions. Numbers
indicate the percentage of cells found in each
gate. Alternatively, WT and TP53/ cells were
stained for the detection of cyclin B (in red) and
cyclin E (in green) (E and F). Representative
immunofluorescence microphotographs of
cells treated with SP600125 for 48 h are shown
in (E) (scale bar¼10mm), while quantitative
results (means SEM; n¼ 3) are reported in (F).
p< 0.05 and p<0.01 (Student’s t-test), as
compared to cells of the same genotype left
untreated.(the cyclin associated with the G1/S phase) (Fig 2E and F and
Fig S2 of Supporting Information). Moreover, in response to
SP600125, the mitotic index (MI; i.e., the fraction of cells that
manifest morphological signs of mitosis) decreased more
rapidly in WT cells than in their TP53/ counterparts (Fig
3A). SP600125 indistinguishably induced the disappearance of
anaphases and telophases in WT and TP53/ cells (Fig 3A),
suggesting that, in the continuative presence of SP600125,
TP53/ cells underwent abortive mitoses. Accordingly, in
response to SP600125, metaphases became disorganized in both
WT and TP53/ cells, as SP600125 abolished the spindle
assembly checkpoint (SAC), stimulated the degradation of
cyclin B in cells with morphologically evident metaphases, andwww.embomolmed.org EMBO Mol Med 4, 500–514increased the number of centrosomes per cell (Fig 3B and C and
Fig S3 of Supporting Information).
These results suggest that SP600125 augments the DNA
content (preferentially of TP53/ cells) in the absence of normal
mitotic chromosome separation, nuclear division (karyokinesis)
and daughter cell formation (cytokinesis). Accordingly, inter-
phase FISH indicates that the SP600125-mediated increase in
DNA content is not accompanied by a proportional increase in
chromosome number but entails a higher hybridization signal,
suggesting chromatid segregation failure (Fig 3D and E). In line
with these observations, HCT 116 cells in which one single
chromosome locus is labelled by GFP (because that locus
contains multiple lacO copies that are stained by transgene- 2012 EMBO Molecular Medicine 503
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Figure 3. p53-modulated effects of SP600125 on
mitotic execution.
A. Mitotic progression in SP600125-treated WT
or TP53/ cells. The total frequency of mitoses
(MI) and the proportion of anaphases plus
telophases among mitotic figures (A–T ratio) as
determined by immunofluorescent microscopy
are shown in human colon carcinoma HCT 116
cells exposed to 30mM SP600125 for the
indicated time (means SEM; n¼5).
B,C. Functional andmorphological characterization
of metaphases upon SP600125 treatment.
Representative immunofluorescence micro-
photographs of mitoses in TP53/ cells trea-
ted with 30mM SP600125 for the indicated
time are shown in (B) and quantitative data are
reported in (C) (means SEM; n¼ 4). Centro-
somes and kinetochores are visualized with
antibodies that recognize g tubulin and CENP-
B, respectively. The activation of the SAC is
monitored by the localization at kinetochore of
BUBR1. Please note that in (C) only (pro-)
metaphases were quantified.
D,E. Interphase FISH of SP600125-treated WT or
TP53/ HCT 116 cells. Representative images
of WT and TP53/ cells treated with 30mM
SP600125 for 24 h are shown in (D). Panel (E)
reports the nuclear volume (normalized to that
of untreated cells), the copy number of
chromosome 7 (in green) and 8 (in red) per
cells, and the centromere hybridization signal
area for chromosomes 7 and 8 (normalized to
those of untreated cells), as determined by
computerized image analyses (means SEM,
n¼ 100 cells) (E).
F-G. Effect of SP600125 and p53 on HCT 116 cells
that contain one single GFP-labelled chromo-
some (LacI-GFP). Panel (F) shows representa-
tive images of WT HCT 116 cells treated with
30mM SP600125 for 48 h, either in control
conditions (siUNR) or upon the siRNA-
mediated p53 knockdown (sip53). Quantitative
data on nuclear volume, number of LacI-GFP
spots/per cell and LacI-GFP signal area (nor-
malized to that of untreated cells) are shown in
(G) (means SEM, n¼100 cells). Please note
that the nuclear volume in (E) and (G) is directly
proportional to ploidy. Scale bar¼10mm.
504expressed LacI-GFP) (Thompson & Compton, 2010) responded
to SP600125 with an increase in DNA content that was not
paralleled by an increase in chromosome number, in particular
upon siRNA-mediated depletion of p53 (Fig 3F andG and Fig S4A
of Supporting Information). In this system, chromosomal GFP
labelling becamemore intense, further suggesting that SP600125
induces chromatin duplication in the absence of chromosomal
separation.
Involvement of MPS1 in the preferential cytotoxicity
of SP600125 against p53-deficient cells
Next, we investigated whether the effects of SP600125 depend
on the inhibition of MPS1 or are mediated by off-target 2012 EMBO Molecular Medicinemechanisms. Transfection-enforced expression of WT MPS1
and more so of an SP600125-refractory MPS1 variant (MPS1-
M602Q) (Schmidt et al, 2005), reduced the capacity of SP600125
to trigger polyploidization in TP53/ cells (Fig 4A and B and
Fig S4B of Supporting Information). The overexpression of
MPS1 (and more so of MPS1-M602Q) also reduced the
frequency of SP600125-treated TP53/ cancer cells manifesting
polyploid S phases and mitoses (Fig 4A, C and D) and staining
positively for cyclin B (Fig 4E). In line with the interpretation
that SP600125 mediates its effects (at least in part) by inhibiting
MPS1, we observed that the siRNA-mediated depletion of MPS1
induced polyploidization more efficiently in TP53/ cells
than in their WT counterparts (Fig 4F and G and Fig S4C ofEMBO Mol Med 4, 500–514 www.embomolmed.org
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506Supporting Information). Similarly, the highly specific MPS1
inhibitor reversine (Santaguida et al, 2010) induced the
preferential polyploidization of TP53/ cells (Fig 4H). None-
theless, depletion or inhibition of MPS1 failed to kill p53-
deficient cellsmore efficiently than theirWT counterparts (Fig 4I
and J and Fig S5 of Supporting Information), suggesting that
MPS1 inhibition is required but not sufficient for the selective
killing of TP53/ cells by SP600125. Finally, the preferential
killing of p53-negative over p53-expressing cells was not
reproduced by the selective depletion of Aurora kinase A,
Aurora kinase B, CHEK1, CHEK2, FLT3, JNK1, JNK2 and MEK1
alone or in various combinations including with MPS1 (Figs S6–
S8 of Supporting Information).
Mechanisms of cell death induced by SP600125
To understand the link(s) between the polyploidization of
TP53/ cells and their enhanced mortality, we performed
detailed videomicroscopic analyses of histone 2B (H2B)-GFP-
expressing WT and TP53/ cells responding to SP600125
(Fig 5A). While there were no differences in the proliferative
potential of untreated WT and TP53/ cells, dramatic
discrepancies became apparent upon exposure to SP600125
(Fig 5B). In the presence of SP600125, indeed, WT cells did not
manifest a mitotic arrest but typically underwent one round of
abortive mitosis featuring a transient phase of chromatin
condensation but not a symmetric metaphase plate, followed by
karyokinesis failure, no cytokinesis and either quiescence (no
further mitosis) or cell death (Fig 5A and B and Video 1 of
Supporting Information). In contrast, more than half of
SP600125-treated TP53/ cells underwent two consecutive
rounds of abortive mitosis (in the absence of karyokinesis and
cytokinesis), leading to increased nuclear size and DNA content
(Fig 5A–D and Video 2 of Supporting Information). Importantly,
in a significant fraction of these cells, the first or second round of
abortive mitosis was followed by the activation of mitotic
catastrophe and cell death (Vitale et al, 2011), which always
occurred 10 h after from mitotic failure (and never during
mitosis) (Fig 5A–D and Video 3 of Supporting Information). In
line with these results, non-proliferating TP53/ cells (cultured
either in presence of low serum concentrations or at high
confluence) were partially protected against SP600125, and their
selective susceptibility to the drug was lost (Fig 6A). This findingFigure 4. Implication of MPS1 in the p53-dependent effects of SP600125 on
A-D. Contribution ofMPS1 to cell cycle progression. WT and TP53/ human colon
plasmid encoding WT MPS1 or an SP600125-resistant variant of MPS1 (MPS
and subjected to cell cycle analysis and assessed for active DNA synthesis
fluorescence). Representative cell cycle distributions and scatter plots are sh
quantitative results (means SEM, n¼ 3) are reported in (B–D). p< 0.05 (
E. Impact of MPS1 on cyclin B and E levels in TP53/ HCT 116 cells. The freque
with the indicated plasmids and treatment with 30mM SP600125 for 24 h
F-J. Effects of MPS1 depletion or inhibition on WT or TP53/ cells. Seventy-two h
MPS1 (siMPS1) (F, G and I) or 48 h after the administration of the indicated
stained to measure DNA content (F–H) or cell death-related parameters (I an
the percentage of cells displaying a>4n DNA content), and quantitative data
illustrate the percentage of dying (PI DiOC6(3)
low) and dead (PIþ) cells, re
TP53/ cells transfected with the same siRNA (I) or treated with the same
 2012 EMBO Molecular Medicineunambiguously proves the causal link between proliferation and
cell death as induced by SP600125. Clonogenic assays
confirmed that SP600125 was more efficient in permanently
reducing the clonogenic potential of TP53/ cells than that of
their WT counterparts (Fig 6B). This loss of proliferative
capacity was accompanied by the activation of mitochondrial
pathways of apoptosis, as documented by the Dcm dissipation
(see above), the release of cytochrome c from mitochondria and
the subsequent activation of caspase-3 and chromatin con-
densation (Fig 6C). The knockdown of pro-apoptotic proteins
such as PUMA and BAX (but not BAK) reduced, while the
depletion of Bcl-2-like apoptosis inhibitors (i.e. Bcl-2, Bcl-XL and
MCL-1) enhanced, the fraction of TP53/ cells succumbing to
SP600125 (Fig 6D). The broad-spectrum caspase inhibitor Z-
VAD-fmk inhibited cell death as well as the appearance of a sub-
diploid population of apoptotic bodies as induced by SP6000125
(Fig 6E).
Altogether, these results suggest that SP600125 kills TP53/
cells secondary to one or two rounds of mitotic abortion and
following the activation of the mitochondrial pathway of
apoptosis. Thus, SP600125 triggers one program of mitotic
catastrophe, preferentially in p53-deficient cells.
p53-deficient cancer cell killing by SP600125 in vitro and
in vivo
SP600125 selectively killed TP53/ (as opposed to WT as well
as to BAX/, CHK2/ and CDKN1A/) HCT 116 cells,
suggesting that its effect is specific (Fig 7A). The depletion of p53
by three distinct siRNAs and the transient transfection of two
dominant-negative p53 mutants (His175 and His273) sensitized
WT HCT 116 cells to SP600125, mimicking the effect of gene
knockout (Fig 7B and C and Fig S2D of Supporting Information).
Similarly, the deletion, depletion or inhibition of p53 sensitized
cell lines other than HCT 116 to SP600125. This applied to
human colorectal cancer RKO cells subjected to the siRNA-
mediated knockdown of p53 (Fig 7D and Fig S2E of Supporting
Information), human osteosarcoma Saos-2 cells expressing p53-
His273 in a doxycycline-inducible fashion (Fig 7E), human
ovarian carcinoma SKOV-3 cells expressing two different
variants of dominant-negative p53 (Fig 7F) and mouse
embryonic fibroblasts (MEFs) lacking Tp53 due to homologous
recombination (Fig 7G). Moreover, SP600125 killed non-the cell cycle.
carcinoma HCT 116 cells were transfected with an empty vector (VSV) or with a
1M602Q), then left untreated () or treated with 30mM SP600125 for 24 h (þ)
(by means of EdU labelling) and histone H3 phosphorylation (by immuno-
own in (A) (numbers refer to the percentage of cells found in each gate) and
Student’s t-test).
ncy of cells expressing cyclin E (in green) or cyclin B (in red) upon transfection
was determined by immunofluorescence (means SEM, n¼ 3).
ours after transfection with a control siRNA (siUNR) or with a siRNA targeting
concentrations of reversine (Rev) (H and J), WT or TP53/ HCT 116 cells were
d J). Representative cell cycle distributions are shown in (F) (numbers refers to
are reported in G–J (means SEM, n¼ 6). In (I and J), white and black columns
spectively (means SEM; n¼6). p<0.05 (Student’s t-test), as compared to
concentration of Rev (J).
EMBO Mol Med 4, 500–514 www.embomolmed.org
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Figure 5.
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508immortalized Tp53/ mouse adult fibroblasts (at early culture
passages) more efficiently than their p53-sufficient counterparts
(Fig 7H). These results suggest that the capacity of SP600125 to
selectively eliminate TP53/ cells can be generalized. Impor-
tantly, not only the absence of p53 but also the continuative
presence of SP600125 is required for efficient cell death
induction, confirming the notion that, in p53-deficient contexts,
SP600125 promotes mitotic aberrations that activate a delayed
program of mitotic catastrophe-induced cell death (Fig S9 of
Supporting Information). Of note, the intraperitoneal adminis-
tration of SP600125 did not affect the growth of p53-proficient
WT HCT 116 tumours xenografted in athymic mice. However,
the same systemic regimen was able to inhibit the growth of
isogenic TP53/ HCT 116 tumours (Fig 7I), underscoring the
notion that SP600125 can mediate selective therapeutic effects
against p53-deficient tumours in vivo.CONCLUDING REMARKS
In this paper, we identified SP600125 as an agent that induces
polyploidization and cell death preferentially in p53-deficient
cells. SP600125 is a multi-kinase inhibitor (Colombo et al, 2010)
and its selective toxicity on TP53/ cells could not be
recapitulated by the selective depletion of several among its
most prominent pharmacological targets including JNK1, JNK2
or MPS1, alone or in combination. This is in contrast with
previous results indicating that SP600125-induced cell death
depends on JNK (Mingo-Sion et al, 2004) and that TP53/ cells
are sensitive to JNK2 depletion (Potapova et al, 2000). Rather,
our results suggest that SP600125 mediates its cytotoxic effects
via amultipronged inhibitory action on several serine/threonine
kinases. Nonetheless, it appears that the inhibition of MPS1 is at
least co-responsible for the preferential effects of SP600125 on
the cell cycle of TP53/ cells. Indeed, transfection with MPS1
(and more so with an SP600125-resistant mutant of MPS1)
limited the polyploidization of TP53/ cells responding to
SP600125. Thus, one of (but not the sole) targets of SP600125
underlying its therapeutic profile against p53-deficient cells is
MPS1. Highly specific MPS1 inhibitors are currently in
preclinical and clinical development (Colombo et al, 2010;
Hewitt et al, 2010; Kwiatkowski et al, 2010; Santaguida et al,
2010; Sliedrecht et al, 2010). However, there are no reports
indicating that such compounds would preferentially kill p53-
deficient cells. It should be noted that the simultaneousFigure 5. Videomicroscopic cell cycle profiling of SP600125 effects on WT and
engineered to express a GFP-histone 2B fusion protein were treated with 30mM
3320min.
A. Representative images. Greek letters refer to individual cells that underwen
condensation (inserts) – or apoptosis (black labelling and cross). Please note th
among TP53/ cells.
B. Cell fate profiles of untreated (control) or SP600125-treated cells with the ind
depict productive cell divisions and aborted mitoses, respectively. Grey dar
C,D. Quantification of cell fates (C) or cell size increments (D) amongWT and TP53
48 h (means SEM, n¼ 100 cells per data point). In (C), only cells generated
tracked and quantified. Scale bar¼ 10mm.
 2012 EMBO Molecular Medicineinhibition of several kinases may exert synergistic pro-apoptotic
actions (Olaussen et al, 2009) and that less specific kinase
inhibitors may have broader anticancer effects than highly
targeted agents, as this has been determined in several clinical
studies (Knight et al, 2010). Thus, the relative non-specificity of
SP600125 may turn into a therapeutic advantage.
Previous groups reported that SP600125 can induce poly-
ploidization in NIH 3T3 MEFs (Schmidt et al, 2005) and in
multiple different human cancer cells, including non-small cell
lung carcinoma (A549) (Miyamoto-Yamasaki et al, 2007), small
lung carcinoma (Calu-1), cervical carcinoma (HeLa; MacCorkle
& Tan, 2004), breast cancer (MCF-7, MDA MB-231, and 21PT)
(Mingo-Sion et al, 2004), osteosarcoma (U2OS) (Kim et al, 2010)
and mantle cell lymphoma cells (Wang et al, 2009). Two
different mechanisms have been proposed for this effect,
namely subsequent rounds of mitosis in the absence of
karyokinesis and cytokinesis or, alternatively, direct endodu-
plication from the G2 phase, due to the inhibition of CDK1. This
latter mechanism has been described to occur in p53-sufficient
cells, and has been attributed to the (indirect) inhibition of CDK1
secondary to that of Aurora kinase A and PLK1 (Kim et al, 2010).
To our knowledge, no systematic studies have been performed
so far to compare the efficacy of SP600125-induced polyploi-
dization in p53-sufficient and p53-deficient cells with one
exception (Kuntzen et al, 2005). In this study, upon SP600125
administration for a short time period (16 h), the authors
observed no differences in cell cycle distribution and cell death
activation in presence or absence of p53. At odds with this, our
results suggest that p53 has a profound impact on the efficacy
(and perhaps the mechanism) of polyploidization as induced by
SP600125. In response to SP600125, TP53/ cells reach higher
level of ploidy than their TP53þ/þ counterparts, and they do so
while contracting their chromosomes periodically in abortive
(pro-)metaphases without forming bona fide metaphase plates,
perhaps because centrosomes aggregate in a single cluster or
they are not able to orchestrate a correct mitotic spindle.
Thereafter, the chromosomes of TP53/ cells decondense with
no signs of anaphase-associated chromosomal movements and
in the absence of complete chromosome separation, as indicated
by FISH and live chromosome labelling. TP53/ cells are able
to go through this round of abortive mitosis up to three times in
the presence of SP600125. In any of these rounds (most often in
the first or second one, rarely in the third one), the
mitochondrial pathway of apoptosis gets activated, most
frequently with a latency of approximately 10 h after mitosis.TP53S/S cells. WT and TP53/ human colon carcinoma HCT 116 cells
SP600125 (time¼ 0min) and then followed by live videomicroscopy for
t abortive mitosis (red labelling and arrowhead) – with transient chromatin
e increase in cell diameter (depicted by the increase in letter size), in particular
icated genotypes, as shown for 50 cells in each condition. Orange and red traits
kening indicates an increase in cell ploidy.
/HCT 116 cells left untreated (Co) or administered with 30mMSP600125 for
by a normal or abortive mitosis within the first 300min of the assays were
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Figure 6. Mechanisms of SP600125-induced cell death in TP53S/S cells.
A. Impact of cell proliferation on cell death triggered by SP600125. TP53/ colon carcinoma HCT 116 cells were maintained in the presence of in the absence of
10% foetal calf serum (FCS) or cultured at normal (n) or high (h) confluence and treated or not with 30mM SP600125 for the indicated time, followed by
cytofluorometric assessment of the cell death-related parameters (means SEM; n¼4). p< 0.05, (Student’s t-test).
B. Clonogenic survival ofWT and TP53/HCT 116 cells. Representative plates as well as quantitative data (means SEM, n¼6, upon normalization to untreated
cells of the same genotype) are shown. p< 0.05 and p< 0.01 (Student’s t-test). Scale bar¼ 3 cm.
C. Mitochondrial cytochrome c release upstream of caspase-3 activation. Cells were stained to visualize cytochrome c (CYTC, green fluorescence), activated
caspase-3 (CASP3a, red fluorescence) and nuclei (Hoechst 33342, blue fluorescence), and the percentage of cells exhibiting diffuse (as opposed to punctuate)
CYTC staining or caspase-3 activation was determined, together with the frequency of apoptotic bodies. Representative fluorescence microphotographs of WT
and TP53/ HCT 116 cells treated with 30mM SP600125 for 72 h and quantitative results at the indicated time (means SEM, n¼4) are shown. Scale
bar¼10mm.
D. Involvement of Bcl-2-like proteins in the death of TP53/ HCT 116 cells as induced by SP600125. Cells were subjected to siRNA-mediated depletion of the
indicated proteins (siUNR¼ control siRNA) for 24 h, followed by the administration of 30mM SP600125 for further 48 h and cytofluorometric assessment of
cell death-related phenomena (means SEM; n¼4). p<0.05 and p< 0.01 (Student’s t-test), as compared to siUNR-trasnfected cells exposed to SP600125.
In (A, C and D), white and black columns illustrate the percentage of dying (PI DiOC6(3)
low) and dead (PIþ) cells, respectively.
E. Effects of Z-VAD-fmk on SP600125-induced manifestations of cell death. TP53/ HCT 116 cells were left untreated (Co) or treated for 72 h with 30mM
SP600125 alone or in combination with 25mMZ-VAD-fmk (Z-VAD), followed by staining with Hoechst 33342 (to assess DNA degradation to a subdiploid level,
subG1) or DiOC6(3)/PI co-staining and cytofluorometry (means SEM, n¼3). p< 0.05 (Student’s t-test).
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3Thus, the killing of TP53/ cells triggered by SP600125 is
closely coupled to abortive mitosis, indicating that SP600125
constitutes a novel inducer of mitotic catastrophe (Vitale et al,
2011). Future studies must decipher the mechanisms that link
SP600125-induced abortive mitosis to apoptosis, and address
the potential clinical utility of this agent.MATERIALS AND METHODS
Unless otherwise indicated, media and supplements for cell culture
were purchased from Gibco-Invitrogen (Carlsbad, CA, USA) and
plasticware from Corning B.V. Life Sciences (Corning, NY, USA).
Chemicals
SP600125 (anthra [1,9-cd] pyrazole-6 (2H)-one) was purchased from
Sigma–Aldrich (St Louis, MO, USA) and stocked as a 30mM solution in
DMSO. Reversine (2-(4-orpholinoanilino)-6-cyclohexylaminopurine)
was purchased from Calbiochem (San Diego, CA, USA) and stocked as
a 10mM solution in DMSO. The pan-caspase inhibitor N-benzyloxy-
carbonyl-Val-Ala-Asp.fluoromethylketone (z-VAD-fmk) was obtained
from Bachem Bioscience (Bubendorf, Switzerland) and stocked as a
50mM solution in DMF. The appropriate amount of DMSO and/or DMF
was always employed for negative control conditions.
Compound screen
A total of 4104 WT HCT 116 cells stably expressing H2B-GFP and
TP53/ HCT 116 cells stably expressing H2B-RFP were seeded at a
ratio of 1:1 in Black/Clear 96-well Imaging Plates (BD Biosciences,
San Diego, CA, USA). Twenty-four hours later, cells were treated
with the agents from the ICCB Known Bioactives Library (Enzo Life
Sciences Inc., Farmingdale, NY, USA) at final concentrations ranging
from 1 to 12mM and kept in a Cytomat 2c automated incubator
(Thermo Fisher Scientific, Waltham, MA, USA). Every 6 h, plates were
instantly transferred to a BD Pathway 855 automated microscope
(BD Biosciences) by means of a robotized Twister II plate handler
(Caliper Life Sciences, Hopkinton, MA, USA), and four view fields in the
centre of each well were acquired using a 20X objective (Olympus,
Center Valley, PA, USA), for a total assay time of 48 h. Images were
analysed for cell density and fluorescence intensity with the BDFigure 7. Effects of the deletion depletion or inhibition of p53 on SP600125
A–H. Lethal effects of SP600125 on p53-deficient cancer cells in vitro.
A–C. Human colon carcinoma HCT 116 cells with different knockout genotypes
siRNAs (B) or transiently transfected (for 24 h) with dominant-negative p53 m
for 72 h as illustrated (30mM where not specified).
D–F. Alternatively human colon carcinoma RKO cells subjected to the siRNA-med
ovarian carcinoma SKOV-3 cells (F) expressing doxycycline (Dox)-inducible p
control conditions or treated with 30mM SP600125 for 72 h.
G,H. Similarly, MEFs (G) or early passage mouse adult fibroblasts (AFs) obtained
susceptibility to SP600125-induced killing. In all cases (A–H), DiOC6(3)/PI co
related variables. White and black columns illustrate the percentage of dy
siUNR, control siRNA. p< 0.05 (Student’s t-test), as compared to WT cells (A
Dox (E and F), treated with the same concentration of SP600125.
I. In vivo growth arrest of p53-deficient tumours by SP600125. WT or TP53/
SP600125-treated groups, 15 mice for vehicle-treated controls), and 1 week
Materials and Methods Section. Tumour size was then routinely monitored b
(two-tailed Student’s t-test), as compared to vehicle-treated mice.
www.embomolmed.org EMBO Mol Med 4, 500–514Attovision software (BD Biosciences) and the slope of growth curves of
each subpopulation over 48 h was calculated by using the linear
regression function of Microsoft Excel (Microsoft Co., Redmond,
WA, USA).
RNA interference
Custom-designed siRNAs targeting MPS1 (siMPS1_1 sense 50-CCCA-
GAGGACUGGUUGAGUdTdT-30 ; siMPS1_2 sense 50-GCAACCACUUAUG-
GUACUGdTdT-30 ; siMPS1_3 sense 50-GCACGUGACUACUUUCAAAdTdT-
30) (Stucke et al, 2004; Xu et al, 2009), p53 (sip53_1 sense 50-
GACUCCAGUGGUAAUCUACdTdT-30; sip53_2 sense 50-GCAUGAACCG-
GAGGCCCAUdTdT-30; sip53_3 sense 50-CUACUUCCUGAAAACAACGdTdT-
30) (Gu et al, 2004; Martinez et al, 2002), AURKB (50-GGAGGAGGAU-
CUACUUGAUTT-30), CHEK1 (sense 50-UCGUGAGCGUUUGUUGAACTT-
30), CHEK2 (sense 50-UGUGUGAAUGACAACUACUTT-30), Bcl-2 (Vicencio
et al, 2009), Bcl-XL (de La Motte Rouge et al, 2007), MCL1 (Kepp et al,
2009) and PUMA (Vitale et al, 2007), were purchased from Sigma-
Proligo (The Woodlands, TX, USA).
Alternatively, siRNA duplexes for the downregulation of FLT3 and MPS1
(siGENOME Smart-pool M-003137 and M-004105, respectively), were
purchased from Dharmacon (Chicago, IL, USA), siRNAs targeting JNK1
(sc-29380) from Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA), siRNAs for the down-regulation of AURKA, JNK2 and MEK1
(SIHK0142, SIHK1224 and SIHK1098, respectively), from Sigma–Aldrich
and siRNAs for the down-regulation of BAK1 and BAX (Hs_BAK1_5 and
Hs_BAX_10 HP Validated siRNAs, respectively) from Qiagen (Hilden,
Germany) (de La Motte Rouge et al, 2007). As a control, a non-targeting
siRNA with a sequence unrelated to the human genome was used
(UNR, sense 50-GCCGGUAUGCCGGUUAAGUdTdT-30).
Cells pre-seeded in 12-well plates were transfected with plasmids
at 80% confluence by means of the Attractene Transfection
reagent (Qiagen) as recommended by the manufacturer, or with
siRNAs at 30–40% confluence by means of the HiPerFect1
transfection reagent (Qiagen), as previously described (Hoffmann
et al, 2008). After 48 or 72 h, transfection efficiency was determined
by immunoblotting.
Immunofluorescence and videomicroscopy
Immunofluorescence microscopy determinations were performed as
previously described (Vitale et al, 2007, 2008). For videomicroscopy,cytotoxicity in several cell lines.
(A), subjected to the transient depletion of p53 (for 24 h) with three distinct
utants (His175 and His273) (C) were left untreated or treated with SP600125
iated knockdown of p53 (D), human osteosarcoma Saos-2 cells (E) or human
53 mutants cultured for 1 week in the absence or presence of Dox were kept in
from the ears mice of the indicated genotype (H) were compared for their
-staining and cytofluorometric analysis were performed to assess cell death-
ing (PI DiOC6(3)
low) and dead (PIþ) cells, respectively (means SEM, n¼3).
and G) cells transfected with the empty vector pCDNA (C), cells not exposed to
HCT 116 cells were injected subcutaneously into athymic mice (30 mice for
later intraperitoneal injections of SP600125 were performed, as described in
y means of a common calliper. Results are reported as means SEM. p<0.05
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The paper explained
PROBLEM:
p53 is the tumour suppression protein whose function is most
frequently lost in human cancer. Thus, more than 20 million
people worldwide live with cancers in which p53 is mutated or
the p53 pathway is interrupted due to the inactivation of
molecules that act either upstream or downstream of p53. The
loss of p53 reduces the efficacy of several conventional
anticancer agents, meaning that p53-deficient tumours are
intrinsically chemoresistant. This work has been designed to
identify small molecules that preferentially kill cancer cells
lacking p53 expression or expressing a mutated p53 variant.
RESULTS:
A screen in which p53-sufficient and p53-deficient tumour cells
were systematically compared for their response to known or
experimental anticancer agents led to the identification of one
molecule, SP600125, that killed p53-deficient cells more
efficiently than their p53-expressing counterparts. This property
of SP600125 was validated on multiple cell lines that differed
relative to the function of the p53 system. In particular, we found
that human p53-deficient cancer cells growing on immunode-
ficient mice responded to chemotherapy with SP600125 in
conditions in which similar cancer cells that express intact p53
failed to do so. We characterized the mechanisms through which
SP600125 can kill p53-deficient (but not p53-sufficient) cancer
cells. We found that p53-sufficient cells underwent a cell cycle
arrest upon exposure to SP600125 and ultimately survived. In
contrast, p53-deficient cells exposed to SP600125 undertook a
series of abortive mitoses (featuring karyokinesis but no
cytokinesis), eventually generating giant cells that finally
underwent apoptotic cell death.
IMPACT:
Altogether, these results delineate a novel strategy to selectively
target cells that lack functional p53. SP600125 exemplifies a
class of drugs that kill p53-deficient cells in a preferential
fashion, based on the incapacity of such cells to undergo a cell
cycle arrest in particular circumstances. Hence, SP600125 (and
its analogues/derivatives) might be used for cancer chemopre-
vention (for eliminating pre-malignant cells that have inacti-
vated p53) or chemotherapy of p53-deficient cancers.
512HCT 116 cells stably expressing a H2B-GFP fusion were grown in 96-
well imaging plates (BD Biosciences) under standard culture condi-
tions and subjected to pulsed observations (every 7min for up to 48 h)
with a BD pathway 855 automated live cell microscope (BD
Biosciences). Images were analysed with the open source software
Image J. Cell fate profile are illustrated as previously published (Rello-
Varona et al, 2010).
In vivo xenograft models
Athymic nu/nu female mice (age 42 days, body weight 20g,
provided by the Institut Gustave Roussy, Villejuif, France in-house
animal facility) were used throughout this study in strict compliance
with widely accepted ethical guidelines for animal experimentation.
Mice were kept in Makrolons type III wire mesh laboratory cages
(Charles River, Boston, MA, USA), under poor germ conditions at
248C and 50–60% humidity, and were allowed for food and water
ad libitum. Light cycle was artificially controlled to provide 14h of
light (from 06:30a.m. to 08:30p.m.). After 4 days of acclimation
period, mice were subcutaneously xenografted with 2106 WT or
TP53/ HCT 116 cells (Vitale et al, 2007). After 1 week, mice were
injected i.p. with 5mg/kg SP600125 (or an equivalent volume of
vehicle) every 2–3 days. Due to its limited solubility in water,
SP600125 was injected in 2% DMSO, 2% polyethylene glycol 600
(PEG600) and 2% Tween 80 in PBS. Statistical analyses were carried
out by means of the SigmaStat package (Systat Software, San Jose, CA,
USA). Statistical significance was determined by means of two-tailed
unpaired Student’s t-test (p<0.05) in the context of a pairwise
comparison procedure. 2012 EMBO Molecular MedicineStatistical procedures
Unless otherwise specified, all experiments were carried out in
triplicate parallel instances and independently repeated at least three
times. Data were analysed with Microsoft Excel (Microsoft) and
statistical significance was assessed by means of two-tailed unpaired
Student’s t-test (p<0.05; p<0.001).
The complete set of experimental and statistical procedures can be
found online as Supporting Information.Author contributions
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